Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-19T21:14:08.800Z Has data issue: false hasContentIssue false

The use of Reserpine in Chronic Psychotic Patients: A Controlled Trial

Published online by Cambridge University Press:  08 February 2018

Lorna Wing*
Affiliation:
Department of Clinical Research, Netherne Hospital

Extract

Reserpine is one of the active alkaloids extracted from the root of the plant Rauwolfia Serpentina. The physiological changes resulting from the use of the drug in animals—such as hypotension, bradycardia, sedation, increased peristalsis, meiosis, etc.—are probably the result of a central action. The precise sites are not known although it seems likely that one of them is the midbrain reticular formation. There is no evidence of any peripheral action, nor of any direct effect on the cortex. The reason for the long latent period, before the drug begins to show an action is still obscure (Lancet Leader, 1955; Mover, 1955; Plummer et al., 1954). The recent work on the pharmacological relationships between Reserpine, Serotonin and the hallucinogens suggests interesting possibilities (Pletscher et al., 1955; Shore et al., 1955).

There is already a considerable literature on the toxic effects of Reserpine, the most serious of which are Parkinsonism, of a post-encephalitic type, and severe depression (Achor et al., 1955; Barsa and Kline, in press; Locket, 1955; Schroeder and Perry, 1955; Stead and Wing, 1955).

Type
Original Articles
Copyright
Copyright © Royal College of Psychiatrists, 1956 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Achor, R. W. P., Hanson, N. O., and Gifford, R. W., J. Amer. Med. Ass., 1955, 159, 841.Google Scholar
Barsa, J. A., and Kiine, N. S., Amer. J. Psychiat. (in press). Google Scholar
Clancy, J., Hoffer, A., Lucy, J., Osmond, H., Smythies, J., and Stefaniuk, B., Ibid, 112, 291.Google Scholar
Davies, D. L., and Shepherd, M., Lancet, 1955, ii, 117.Google Scholar
Folkard, M. S., Personal communication. Work to be published, 1956.Google Scholar
Folkson, A., and May, A. R., Brit. Med. J., 1955, ii, 1121.Google Scholar
Freudenberg, R. K., 1956 (in press).Google Scholar
Glynn, J. D., J. Neurol. Neurosurg. Psychiat., 1955, 18, 225.Google Scholar
Green, F. H. K., Lancet, 1954, ii, 1085.Google Scholar
Hill, A. Bradford, Brit. Med. Bull., 1951, 7, 278.Google Scholar
Kline, N. S., Ann. N. Y. Acad. Sci., 1954, 59, 107.Google Scholar
Lancet Leader, 1955, i, 548.Google Scholar
Lasagna, L., J. Chronic dis., 1955, 1, 353.Google Scholar
Locket, S., Brit. Med. J., 1955, i, 809.Google Scholar
Lucero, R. J., and Meyer, B. T., J. Clin. Psychol., 1951, 7, 250.Google Scholar
Idem , Ibid., 1953, 9, 192.Google Scholar
Mover, J. H., Arch. Int. Med., 1955, 96, 518.Google Scholar
Noce, R. H., Williams, D. B., and Rapaport, W., J. Amer. Med. Ass., 1954, 153, 821.Google Scholar
Pletscher, A., Shore, P. A., and Brodie, B. B., Science, 1955, 122, 374.Google Scholar
Plummer, A. J., Earl, A., Schneider, J. A., Trapold, J., and Barret, W., Ann. N. Y. Acad. Sci., 1954, 59, 8.Google Scholar
Sarwer-Foner, G. J., and Ogle, W., Canad. Med. Ass. J., 1955, 73, 187.Google Scholar
Schroeder, H. A., and Perry, H. M., J. Amer. Med. Ass., 1955, 159, 839.Google Scholar
Shore, P. A., Science, 1955, 122, 254.Google Scholar
Somerness, M. D., Lucero, R. J., Hamlon, J. S., Erickson, J. L., and Matthews, R., Arch. Neurol. Psychiat., 1955, 74, 316.Google Scholar
Stanton, A. H., and Schwartz, M. S., The Mental Hospital, 1954. London: Tavistock Publications.Google Scholar
Stead, J. S., and Wing, J. K., Lancet, 1955, i, 823.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.